Adial Pharmaceuticals Inc
NASDAQ:ADIL
Adial Pharmaceuticals Inc
NASDAQ:ADIL
Price:
1.83
USD
6.4%
Market Closed
Market Cap:
$2m
Relative Value
There is not enough data to reliably calculate the relative value of ADIL.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ADIL
Relative Value
Base Case
Not Available
Multiples Across Competitors
ADIL Competitors Multiples
Adial Pharmaceuticals Inc Competitors
Adial Pharmaceuticals Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Adial Pharmaceuticals Inc
NASDAQ:ADIL
|
2m USD | 0 | -0.3 | 0.5 | 0.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
946.1B USD | 14.5 | 45.8 | 30.9 | 33 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
586.8B USD | 6.2 | 21.9 | 15.2 | 18.7 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
261.6B CHF | 4.3 | 20.5 | 12.1 | 13.6 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
224.9B GBP | 5.1 | 29.5 | 16.4 | 23 | |
| CH |
|
Novartis AG
SIX:NOVN
|
232.1B CHF | 5.3 | 21.5 | 13.3 | 17.1 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 4.5 | 15.9 | 9.9 | 12 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.8 | 8 | 9.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
154.4B USD | 2.5 | 19.9 | 7.7 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121B USD | 2.5 | 17.2 | 7.2 | 8.9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
